Preventive and therapeutic effects of alpha-acid glycoprotein in mice infected with B. anthracis

• Published in: Bulletin of experimental biology and medicine Vol. 140; no. 4; pp. 439 - 444
• Main Authors: Shemyakin, I G, Pukhalsky, A L, Stepanshina, V N, Shmarina, G V, Aleshkin, V A, Afanas'ev, S S
• Format: Journal Article
• Language: English
• Published: United States 01.10.2005
• Subjects: Animals; Anthrax - drug therapy; Anthrax - immunology; Anthrax - prevention & control; Bacillus anthracis; Cytokines - blood; Humans; Mice; Mice, Inbred BALB C; Orosomucoid - administration & dosage; Orosomucoid - therapeutic use
• ISSN: 0007-4888
• DOI: 10.1007/s10517-005-0514-9

We studied the effects of alpha1-acid glycoprotein preparations on the survival rate of BALB/c mice infected with the lethal dose of B. anthracis STI-1. Apart from native alpha1-acid glycoprotein from donor blood, we studied 3 glycoforms differing in the affinity for concanavalin A and structure of carbohydrate chains. The protective effect of alpha1-acid glycoprotein preparations did not depend on its dose and was observed 3 months after treatment (0.3 mg per mouse). The protective effect was revealed in mice receiving alpha1-acid glycoprotein preparations 2 h before infection and 24 h after inoculation of the bacterial culture. In the latter case the survival rate of animals was much higher compared to that observed in preventive administration of alpha1-acid glycoprotein. The protective effect practically did not depend on the time of treatment with glycoforms. Pretreatment with alpha1-acid glycoprotein preparations significantly decreased plasma interferon-gamma concentration. Administration of the test preparations 24 h after infection decreased the concentration of tumor necrosis factor-alpha.